All In Biotech

Drug Trial Radar · NCT05521022

Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02

Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Sep 1, 2022

Primary completion

Mar 1, 2025

Study completion Mar 1, 2025

Sponsor

Lead sponsor
Attralus, Inc.Industry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Aug 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.

Conditions

  • Amyloidosis; Systemic

Interventions

  • AT-02Drug

    AT-02 via IV infusion

  • AT-02 (Placebo)Other

    Normal saline solution via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of treatment-emergent adverse events (TEAEs) from Day 1 to end of study (EOS).Time frame: Up to 57+/-7 days
  2. Incidence of dose-limiting toxicities (DLTs) in subjects with systemic amyloidosis.Time frame: Up to 85+/-7 Days
  3. Incidence and frequency of abnormal and clinically significant abnormal clinical laboratory parameter values.Time frame: Up to 85+/-7 Days
  4. Incidence of treatment-emergent anti-drug antibodies (ADA)Time frame: Up to 85+/-7 Days

Locations

11 sites in 2 countries. Site status is shown where the registry gives one.

  • Midwest Heart and Vascular

    Overland Park, Kansas · Recruiting

  • Johns Hopkins

    Baltimore, Maryland · Recruiting

  • St. Luke's Hospital of Kansas City

    Kansas City, Missouri · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • OHSU (Oregon Health & Science University)

    Portland, Oregon · Recruiting

  • Penn Presbyterian Medical Center

    Philadelphia, Pennsylvania · Recruiting

  • Q-Pharm Pty Ltd

    Herston, Queensland, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • Box Hill Hospital

    Box Hill, Victoria, Australia · Recruiting

  • Royal Perth Hospital

    Perth, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.